Ionis reveals no new safety concerns over inotersen, will file imminently in EU & USA

2 November 2017
2019_biotech_test_vial_discovery_big

Ionis Pharmaceuticals (Nasdaq: IONS) has presented new data from its Phase III NEURO-TTR study, evaluating inotersen in patients with a hereditary form of the rare disease ATTR amyloidosis.

The results, which are currently being presented at the first European ATTR Amyloidosis meeting in Paris, show significant benefit compared to placebo in both co-primary endpoints, after both eight and 15 months.

The efficacy of inotersen was measured according to a commonly-used quality of life assessment measure, and a disease severity assessment.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology